Medical Device News Magazine

Envoy Medical Early Feasibility Study of Breakthrough Fully Implanted Cochlear Implant Now Underway

First Patient Receives Fully Implanted Acclaim® Cochlear Implant

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Envoy Medical Corporation, a hearing health company focused on providing innovative technologies across the hearing loss spectrum, today announced the first patient has been enrolled and implanted in the Acclaim® Cochlear Implant early feasibility study at Mayo Clinic in Rochester, Minn.

This surgery marks a key milestone for Envoy Medical on the road toward bringing the Acclaim Cochlear Implant to market. If approved by the FDA, the Acclaim would be the first-of-its-kind cochlear implant designed to be fully implanted and use the ear, rather than a microphone, to pick up sound.

The implantation surgery was conducted by Colin Driscoll, MD, practicing neurotologist, professor of otolaryngology – head and neck surgery at Mayo Clinic, and principal investigator for this study. After a healing period, the Acclaim Cochlear Implant will be activated by Aniket Saoji, PhD, associate professor of otolaryngology – head and neck surgery at Mayo Clinic and co-investigator of the study. Both investigators serve on Envoy Medical’s Cochlear Implant Advisory Board.

“We at Envoy Medical are extremely proud that our Acclaim early feasibility study is taking place at Mayo Clinic. There is a strong medical device history and culture here in Minnesota, and we are honored to add to that legacy,” said Brent Lucas, CEO of Envoy Medical. “This study is an important step towards demonstrating whether the fully implanted Acclaim Cochlear Implant works as it was designed, turning the page to a new chapter in cochlear implants. We hope to change the status quo within the hearing industry, and I am so proud of our team for bringing this breakthrough technology to fruition—implantable medical devices are not for the faint of heart.”

Based on an Investigational Device Exemption (IDE) granted by the U.S. Food and Drug Administration (FDA), the early feasibility study for the Acclaim is expected to last 18 months and will be followed by a pivotal trial to support a Premarket Approval (PMA) application to the FDA.

Of the estimated 1.4-4 million adults with significant hearing loss in the U.S. who could benefit from cochlear implants, only roughly 5 percent of eligible adult candidates use cochlear implants.[1] Potential adult recipients often wait longer than they should to get existing partially implanted cochlear implants, and a reason often cited is the amount of external hardware.[2]

Patients interested in learning more about the study should contact Amy Pajula, customer experience manager, at apajula@envoymedical.com for more information.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”